About Eligo Bioscience
Eligo Bioscience is a company based in Paris (France) founded in 2014 by David Bikard and Xavier Duportet. Eligo Bioscience has raised $52.26 million across 7 funding rounds from investors including Khosla Ventures, Bpifrance and European Union. Eligo Bioscience offers products and services including GEM Platform. Eligo Bioscience operates in a competitive market with competitors including eGenesis, Beam Therapeutics, Korro Bio, Insmed and Scribe Therapeutics, among others.
- Annual Revenue$1.92 M (USD)-16as on Dec 31, 2021
- Net Profit-$5.16 M (USD)-183as on Dec 31, 2021
- EBITDA-$7.47 M (USD)-120as on Dec 31, 2021
- Total Equity Funding$52.26M (USD)
in 7 rounds
- Latest Funding Round$5M (USD), Grant
May 2025
- InvestorsKhosla Ventures
& 5 more
Products & Services of Eligo Bioscience
Eligo Bioscience offers a comprehensive portfolio of products and services, including GEM Platform.
Platform for in vivo editing of microbiome genes to influence health.
Funding Insights of Eligo Bioscience
Eligo Bioscience has successfully raised a total of $52.26M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $5 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $52.26M
- Total Rounds 7
- Last Round Grant — $5M
- First Round $2.2M
(Jul 2015)
- Investors Count 6
All 7 funding rounds of Eligo Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2025 | $5M | Grant | – | – | |
| Nov 2023 | $30.06M | Series B | – | Sanofi Ventures | |
| Mar 2022 | $55,679 | Grant | – | – | |
| Apr 2019 | $3.1M | Grant | – | – | |
| Sep 2017 | $20M | Series A | – | Khosla Ventures | |
| Sep 2017 | $2M | Grant | – | – | – |
| Jul 2015 | $2.2M | Seed | – | Seventure Partners | – |
6 investors in total: 6 institutional.
Investors in Eligo Bioscience
Eligo Bioscience has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Khosla Ventures, Bpifrance and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life-Sciences focused Early stage Corporate VC Firm investing in the US | – | sanofiventures.com | Paris, France | |
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US | – | seventure.fr | Paris, France | |
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Eligo Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eligo Bioscience
2 people are tracked at Eligo Bioscience (2 in leadership).
| Name | Role | Group |
|---|---|---|
David Bikard | Co-Founder | Leadership |
Xavier Duportet | Co-Founder & CEO | Leadership |
Complete people profiles for Eligo Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Eligo Bioscience
3 dated milestones of Eligo Bioscience across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Eligo Bioscience is founded.
- Funding First funding round of $2.2M.
- Funding Latest funding round, Grant, of $5.0M.
Competitors of Eligo Bioscience
Eligo Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as eGenesis, Beam Therapeutics, Korro Bio, Insmed and Scribe Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| egenesisbio.com | 2015 | Cambridge, United States | $481.42M | 94 | Gene transplantation platform for humanizing pig cells is developed. | |
| beamtx.com | 2017 | Cambridge, United States | $222M | 340 | Developer of gene therapy using CRISPR base editing to treat diseases | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| insmed.com | 1999 | Bridgewater, United States | – | 912 | Developer of small molecule inhibitors for rare lung diseases | |
| scribetx.com | 2018 | Alameda, United States | $120M | – | A CRISPR-based gene-editing platform is developed for therapeutic applications. | |
| tesseratherapeutics.com | 2017 | Cambridge, United States | $610M | 149 | New genome engineering technology is provided for treating multiple diseases. | |
| locus-bio.com | 2015 | Raleigh, United States | $67.33M | 74 | Developer of therapeutics for infectious disease and inflammatory indications | |
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. |
Detailed competitors of Eligo Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Eligo Bioscience
The website of Eligo Bioscience (eligo.bio) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 31.7% vs previous month
Latest news on Eligo Bioscience
Complete news archive for Eligo Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Eligo Bioscience
10 companies that operate in the same segment as Eligo Bioscience (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Eligo Bioscience
Eligo Bioscience was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Eligo Bioscience is headquartered in Paris, France.
Xavier Duportet is the current CEO of Eligo Bioscience. They have also founded this company.
Eligo Bioscience is a funded company, having raised a total of $52.26M across 7 funding rounds to date. The company's 1st funding round was a Seed of $2.2M, raised on Jul 2015.
Annual revenue of Eligo Bioscience is $1.92M as on Dec 31, 2021.
Eligo Bioscience was founded in 2014 in Paris, France, within the biotechnology sector. In vivo gene editing tools are provided to modify the microbiomes genetic composition. Diseases influenced by particular bacterial genes are targeted through this platform. Interactions between microbial communities and the host immune system are addressed in therapeutic applications. Operations focus on advancing microbiome-based interventions for health conditions.
Eligo Bioscience's top competitors include eGenesis, Tessera Therapeutics and Korro Bio.
Eligo Bioscience offers GEM Platform.
Eligo Bioscience has 6 investors. Key investors include Khosla Ventures, Bpifrance, European Union, Sanofi Ventures, and Seventure Partners.
Eligo Bioscience operates through Eligo Bioscience.